Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision.

[1]  E. Clini,et al.  Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution , 2021, Frontiers in Pharmacology.

[2]  C. Ryerson,et al.  Diagnostic Classification of Interstitial Lung Disease in Clinical Practice. , 2021, Clinics in chest medicine.

[3]  Nan Tang,et al.  Stem cells in pulmonary alveolar regeneration , 2021, Development.

[4]  Mark G. Jones,et al.  Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2020, Pharmacology & therapeutics.

[5]  Mario Silva,et al.  Interstitial lung disease in Sjögren's syndrome: a clinical review. , 2020, Clinical and experimental rheumatology.

[6]  Toshihiro Ito,et al.  Spred2-deficiency enhances the proliferation of lung epithelial cells and alleviates pulmonary fibrosis induced by bleomycin , 2020, Scientific Reports.

[7]  M. Selman,et al.  The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis. , 2020, American journal of respiratory cell and molecular biology.

[8]  M. Foley,et al.  CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis , 2020, Respiratory Research.

[9]  J. Catravas,et al.  HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF) , 2020, International journal of molecular sciences.

[10]  J. Verschakelen,et al.  Desquamative interstitial pneumonia: a systematic review of its features and outcomes , 2020, European Respiratory Review.

[11]  L. Richeldi,et al.  Pamrevlumab for the treatment of idiopathic pulmonary fibrosis , 2020, Expert opinion on investigational drugs.

[12]  J. Catravas,et al.  Post-treatment with a heat shock protein 90 inhibitor prevents chronic lung injury and pulmonary fibrosis, following acute exposure of mice to HCl , 2020, Experimental lung research.

[13]  M. Harlander,et al.  Acute interstitial pneumonia triggered by strenuous exercise , 2020, Respiratory Medicine Case Reports.

[14]  T. Corte,et al.  Nonspecific Interstitial Pneumonia , 2020, Seminars in Respiratory and Critical Care Medicine.

[15]  K. Brown,et al.  Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. , 2020, The Lancet. Respiratory medicine.

[16]  M. Königshoff,et al.  Chronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells. , 2020, Cellular signalling.

[17]  C. Ryerson,et al.  Progression of fibrosing interstitial lung disease , 2020, Respiratory Research.

[18]  L. Ebner,et al.  Meta-analysis of the radiological and clinical features of Usual Interstitial Pneumonia (UIP) and Nonspecific Interstitial Pneumonia (NSIP) , 2020, PloS one.

[19]  M. Cho,et al.  Genome-Wide Association Study: Functional Variant rs2076295 Regulates Desmoplakin Expression in Airway Epithelial Cells , 2020 .

[20]  M. Kreuter,et al.  Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. , 2020, The Lancet. Respiratory medicine.

[21]  C. Barber,et al.  Identifying causation in hypersensitivity pneumonitis: a British perspective , 2019, BMJ Open Respiratory Research.

[22]  M. Selman,et al.  The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. , 2019, Cellular signalling.

[23]  Seidai Sato,et al.  Fibrocytes and Fibroblasts - where are we now. , 2019, The international journal of biochemistry & cell biology.

[24]  S. Nava,et al.  Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. , 2019, Respiratory medicine.

[25]  Xiaodong Han,et al.  The Shh/Gli signaling cascade regulates myofibroblastic activation of lung-resident mesenchymal stem cells via the modulation of Wnt10a expression during pulmonary fibrogenesis , 2019, Laboratory Investigation.

[26]  T. Corte,et al.  Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) , 2019, Drugs.

[27]  J. Egen,et al.  TAZ is required for lung alveolar epithelial cell differentiation after injury. , 2019, JCI insight.

[28]  M. Ferrada,et al.  Pulmonary Manifestations of Primary Sjögren's Syndrome: Underlying Immunological Mechanisms, Clinical Presentation, and Management , 2019, Front. Immunol..

[29]  Lin Chen,et al.  Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway , 2019, Cell cycle.

[30]  V. Thannickal,et al.  Developmental pathways in the pathogenesis of lung fibrosis. , 2019, Molecular aspects of medicine.

[31]  M. Molina-Molina,et al.  Interstitial Lung Diseases in Developing Countries , 2019, Annals of global health.

[32]  J. Horowitz,et al.  Mechanisms for the Resolution of Organ Fibrosis. , 2019, Physiology.

[33]  G. Raghu,et al.  Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. , 2019, The Lancet. Respiratory medicine.

[34]  Satoshi Noguchi,et al.  YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer , 2018, International journal of molecular sciences.

[35]  C. Nomura,et al.  Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification , 2018, Radiologia brasileira.

[36]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[37]  C. Howlett,et al.  Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis , 2018, Respiratory Research.

[38]  N. Vaziri,et al.  New insights into TGF-β/Smad signaling in tissue fibrosis. , 2018, Chemico-biological interactions.

[39]  S. Dupont,et al.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. , 2018, The Lancet. Respiratory medicine.

[40]  W. Seeger,et al.  The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis , 2018, Respiratory Research.

[41]  B. Stripp,et al.  Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. , 2018, JCI insight.

[42]  T. Sugai,et al.  Distinct Profiles of CD163-Positive Macrophages in Idiopathic Interstitial Pneumonias , 2018, Journal of immunology research.

[43]  T. Sugai,et al.  Distinct Profiles of CD 163-Positive Macrophages in Idiopathic Interstitial Pneumonias , 2018 .

[44]  Yuan-jue Zhu,et al.  Association between nonspecific interstitial pneumonia and presence of CD20+ B lymphocytes within pulmonary lymphoid follicles , 2017, Scientific Reports.

[45]  Melanie E Moses,et al.  ROCK regulates the intermittent mode of interstitial T cell migration in inflamed lungs , 2017, Nature Communications.

[46]  A. Shilatifard,et al.  Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span , 2017, The Journal of experimental medicine.

[47]  K. Meyer Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis , 2017, Expert review of respiratory medicine.

[48]  A. Jegga,et al.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis. , 2017, JCI insight.

[49]  W. Seeger,et al.  Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. , 2017, Cell stem cell.

[50]  M. Kolb,et al.  Heat shock protein: a hot topic in idiopathic pulmonary fibrosis , 2017, European Respiratory Journal.

[51]  W. Seeger,et al.  Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung Fibrosis. , 2017, Cell stem cell.

[52]  B. Stripp,et al.  Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. , 2016, JCI insight.

[53]  S. Gharib,et al.  Lung Pericytes and Resident Fibroblasts: Busy Multitaskers. , 2016, The American journal of pathology.

[54]  T. Panchabhai,et al.  Lymphocytic Interstitial Pneumonia. , 2016, Clinics in chest medicine.

[55]  P. Chambon,et al.  Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. , 2016, The Journal of clinical investigation.

[56]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[57]  Y. Kondoh,et al.  Acute and subacute idiopathic interstitial pneumonias , 2016, Respirology.

[58]  D. Thickett,et al.  Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis , 2016, BMC Pulmonary Medicine.

[59]  A. Ryan,et al.  Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. , 2016, Immunity.

[60]  S. Zucker,et al.  Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts , 2016, Respiratory Research.

[61]  K. Flaherty,et al.  Idiopathic non‐specific interstitial pneumonia , 2016, Respirology.

[62]  S. Harari,et al.  Smoking‐related idiopathic interstitial pneumonia: A review , 2016 .

[63]  P. Chambon,et al.  Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. , 2016, The Journal of clinical investigation.

[64]  M. Kreuter,et al.  Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives , 2015, BioMed research international.

[65]  S. Bellusci,et al.  Evidence for the involvement of fibroblast growth factor 10 in lipofibroblast formation during embryonic lung development , 2015, Development.

[66]  S. Shin,et al.  Inflammatory Diseases of the Lung Induced by Conventional Cigarette Smoke: A Review. , 2015, Chest.

[67]  D. Lynch,et al.  American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[68]  Alexander Pautsch,et al.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[69]  C. Redlich,et al.  Asbestosis and environmental causes of usual interstitial pneumonia , 2015, Current opinion in pulmonary medicine.

[70]  H. Binder,et al.  Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis , 2015, PloS one.

[71]  J. Liao,et al.  The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis , 2015, Pharmacological Reviews.

[72]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[73]  Athol U. Wells,et al.  Interstitial lung disease in connective tissue disease—mechanisms and management , 2014, Nature Reviews Rheumatology.

[74]  S. Menon,et al.  ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. , 2014, American journal of physiology. Cell physiology.

[75]  Buqu Hu,et al.  Chitinase 3–Like 1 Suppresses Injury and Promotes Fibroproliferative Responses in Mammalian Lung Fibrosis , 2014, Science Translational Medicine.

[76]  C. Vancheri,et al.  Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review , 2014, Insights into Imaging.

[77]  Xiaozhi Wang,et al.  Alveolar epithelial cells undergo epithelial-mesenchymal transition in acute interstitial pneumonia: a case report , 2014, BMC Pulmonary Medicine.

[78]  Joyce S Lee,et al.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model. , 2014, Chest.

[79]  V. Thannickal,et al.  Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[80]  K. Ichikado High-resolution computed tomography findings of acute respiratory distress syndrome, acute interstitial pneumonia, and acute exacerbation of idiopathic pulmonary fibrosis. , 2014, Seminars in ultrasound, CT, and MR.

[81]  S. Rosselot Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[82]  M. Andrianifahanana,et al.  Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  J. Bates,et al.  Stem cells and cell therapies in lung biology and diseases: conference report. , 2013, Annals of the American Thoracic Society.

[84]  W. Altemeier,et al.  Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. , 2013, American journal of respiratory and critical care medicine.

[85]  F. Bonella,et al.  CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases. , 2013, Respiratory medicine.

[86]  Y. Moodley,et al.  Anti-Inflammatory Effects of Adult Stem Cells in Sustained Lung Injury: A Comparative Study , 2013, PloS one.

[87]  E. Ansó,et al.  Matrix Metalloproteinase (MMP)-1 Induces Lung Alveolar Epithelial Cell Migration and Proliferation, Protects from Apoptosis, and Represses Mitochondrial Oxygen Consumption* , 2013, The Journal of Biological Chemistry.

[88]  A. Oikonomou,et al.  A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis , 2013, Journal of Translational Medicine.

[89]  L. Ortiz,et al.  Cell therapy trials for lung diseases: progress and cautions. , 2013, American journal of respiratory and critical care medicine.

[90]  M. Glassberg,et al.  Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. , 2013, American journal of respiratory and critical care medicine.

[91]  B. Ghanim,et al.  Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. , 2013, Journal of proteomics.

[92]  Cynthia Davidson,et al.  MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. , 2012, American journal of respiratory cell and molecular biology.

[93]  T. Colby,et al.  Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients , 2012, BMC Pulmonary Medicine.

[94]  S. Glaser,et al.  General mechanisms of nicotine‐induced fibrogenesis , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  A. Fabre,et al.  The hedgehog system machinery controls transforming growth factor-β-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. , 2012, The American journal of pathology.

[96]  M. Gaxiola,et al.  Role of Sonic Hedgehog in idiopathic pulmonary fibrosis. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[97]  B. Hinz Mechanical aspects of lung fibrosis: a spotlight on the myofibroblast. , 2012, Proceedings of the American Thoracic Society.

[98]  J. Massagué TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[99]  N. Sverzellati,et al.  An integrated approach in the diagnosis of smoking-related interstitial lung diseases , 2012, European Respiratory Review.

[100]  I. Rosas,et al.  Autophagy in Idiopathic Pulmonary Fibrosis , 2012, PloS one.

[101]  Konstantinos Karagiannis,et al.  Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. , 2012, International journal of oncology.

[102]  Michael J. Cronce,et al.  Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition , 2011, Proceedings of the National Academy of Sciences.

[103]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[104]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[105]  D. Guinee Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities. , 2010, Archives of pathology & laboratory medicine.

[106]  M. Armanios Syndromes of telomere shortening. , 2009, Annual review of genomics and human genetics.

[107]  G. Raghu,et al.  Telomere shortening in familial and sporadic pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[108]  Athol Wells,et al.  Idiopathic nonspecific interstitial pneumonia: Report of an American thoracic society project , 2008 .

[109]  Richard I. Morimoto,et al.  Adapting Proteostasis for Disease Intervention , 2008, Science.

[110]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[111]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[112]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[113]  Naftali Kaminski,et al.  Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.

[114]  David A Lynch,et al.  Idiopathic interstitial pneumonias: CT features. , 2005, Radiology.

[115]  K. Kuwano,et al.  The p53–Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia , 2005, Journal of Clinical Pathology.

[116]  A. Nicholson,et al.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. , 2005, The American journal of pathology.

[117]  Dorsett D. Smith Diagnosis and Initial Management of Nonmalignant Diseases Related to Asbestos , 2003 .

[118]  N. Siafakas,et al.  Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. , 2005, Chest.

[119]  M. Burdick,et al.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.

[120]  Gerald J Berry,et al.  Lymphoid interstitial pneumonia: a narrative review. , 2002, Chest.

[121]  H. Ihn Pathogenesis of fibrosis: role of TGF-β and CTGF , 2002 .

[122]  Koichiro Yoshida,et al.  MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis , 2002, The Journal of pathology.

[123]  Jonathan Haines,et al.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. , 2002, American journal of respiratory and critical care medicine.

[124]  A. Nicholson,et al.  Reactive pulmonary lymphoid disorders , 1995, Histopathology.

[125]  K. Adler,et al.  The myofibroblast in pulmonary fibrosis. , 1983, Chest.